Anxious to protect her children, Stanford immunology researcher enrolls her two young children Pfizer’s COVID-19 vaccine clinical trial for kids.
A Stanford-developed anti-cancer therapy currently in clinical trials may also reduce vascular inflammation in heart disease.
Doctors and researchers are prioritizing a digital-first approach as they adapt clinical trials to the COVID-19 pandemic.
Stanford Medicine researcher John Ioannidis calls for transparency and the sharing of data, a lesson learned through COVID-19.
Stanford Medicine researchers are investigating SARS-CoV-2 to address the COVID-19 pandemic and ultimately help restore normalcy to society.
Stanford infectious disease expert Yvonne Maldonado, MD, describes principles for developing safe and effective COVID-19 vaccines for everyone.
Technology that sends blood sugar-level updates to their smartphones improves outcomes for young people with type 1 diabetes, a Stanford trial shows.
Many early clinical studies of COVID-19 fail to meet quality standards, raising concerns that the data could be of little meaningful use, research finds.
A Stanford microbiologist describes the invigorating, yet sobering race to develop an effective vaccine against COVID-19.
The Innovative Medicines Accelerator builds on existing programs at Stanford — but fills in gaps to help researchers turn ideas into drugs.
Stanford Medicine will be the first to use a new technology that aims to heighten precision of radiation therapy in cancer patients.
In a clinical trial, a tiny prosthetic retinal device invented by a Stanford researcher has proved its potential ability to restore eyesight to the blind.
A study links ulcerative colitis to the depletion of important acids ordinarily produced by a set of gut microbes mysteriously missing in action.
At a recent talk on campus, Amy Abernethy, an FDA principal deputy commissioner, discussed her career and her work to facilitate clinical advances.
A new Stanford study in children with autism showed the value of teaching parents how to use everyday interactions to motivate their children to speak.
A therapy delayed the onset of Type 1 diabetes in at-risk people by about two years, new results from a clinical trial show.
